Laser and TLR [toll-like receptor]-agonist immunotherapy: A Novel autologous melanoma vaccine study
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Imiquimod (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 06 May 2015 Biomarkers information updated
- 04 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Jun 2007 New trial record.